KTTA:NASDAQPasithea Therapeutics Corp. analysis
Data as of Oct 6, 2026 - not real-time
- Latest price
- $0.44
- Risk: high
- 9/10High risk
Summary
The moving-average structure behind Pasithea Therapeutics Corp. is bearish at $0.4422, with short-term averages lagging the long-term ones. Across the trailing 30 sessions it lost 12.4%. With RSI at 32.3 the momentum picture is approaching oversold, alongside a bearish MACD signal. Recent trading has carved out support near $0.4402 and resistance around $0.5990.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 578.4% above where the shares trade now.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 52.5%, a beta of 1.36 and a maximum drawdown of 69.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 578.4% above where the shares trade now.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 52.5%, a beta of 1.36 and a maximum drawdown of 69.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Top market events
- -- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference September 9-11...
- Pasithea Therapeutics Announces Presentation Of Initial PAS-004 Clinical Data From Ongoing Phase 1/1B Clinical Trial In...
- streetinsider22dPasithea to present PAS-004 trial data at neurofibromatosis conferencePasithea Therapeutics Corp.
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.69
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.69
- Analyst targets imply +578.4% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +578.4% versus the current price
- Negative return on equity of -65.5%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-1.0
ROE-65.49%
ROA-36.00%
P/B Ratio0.3
Op. Cash Flow$-17781584
Free Cash Flow$-12165350
Industry P/E29.8
Technical analysis
TrendBearish
RSI32.3
Support$0.44
Resistance$0.60
MA 20$0.50
MA 50$0.51
MA 200$0.69
MACDBearish
VolumeDecreasing
Fear & Greed Index94.48
Valuation
Target Price$3.00
Upside/Downside578.43%
GradeUndervalued
TypeBlend
Risk assessment
Beta1.36
Volatility52.46%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.